A Phase 3, Multicenter, Open Label Study to Assess the Safety and Efficacy of Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Associated Liver Disease Who Underwent Liver Transplantation.

Trial Profile

A Phase 3, Multicenter, Open Label Study to Assess the Safety and Efficacy of Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Associated Liver Disease Who Underwent Liver Transplantation.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Hepatitis B immune globulin (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms Nabi-HB-SC
  • Sponsors Biotest Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned initiation date changed from 1 Apr 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top